Materials and methods for treating diseases caused by genetic disorders using aminoglycosides and derivatives thereof which exhibit low nephrotoxicity
Various aspects related to the preparation of congeners of the aminoglycosides gentamicin such as the congener C2 and using this compound or derivatives thereof and pharmaceutically active salts to treat diseases that involve genetic mutations which introduce a missense or premature stop codon into a gene. Still other aspects include treating human or animal patients with the gentamicin congener C2 and derivatives and pharmaceutical salt thereof to overcome, or to at least mitigate, the symptoms of disease and disorders such as some forms of Becker's or Duchenne muscular dystrophy, Hurler's Syndrome and Cystic Fibrosis that have as their etiology the presence of a premature stop codon in a gene whose proper expression is necessary for good health.
1. A method of treating a genetic disease, comprising the steps of:
identifying a patient, wherein the patient exhibits a pathology that includes the imposition of a stop codon in the open reading frame of an otherwise functional gene, and wherein the pathology is selected from the group consisting of Duchenne Muscular Dystrophy, cystic fibrosis, Hurler's syndrome, and Becker muscular dystrophies; and
formulating a mixture of a therapeutically effective dose of an aminoglycoside enriched in an isolated and purified compound having the following formula, or a pharmaceutically acceptable salt thereof:
wherein, R 1 and R 3 are H, and R 2 is CH 3 , and wherein the compound is present in said formulation at a level sufficient to reduce the cellular toxicity of the aminoglycoside; and administering a therapeutically effective dose of said formulation to the patient.
2. The method described in claim 1 , wherein the patient is a human.
3. A method of treating genetic disease, comprising the steps of:
identifying a patient, wherein the patient exhibits a pathology that includes the imposition of a stop codon in the open reading frame of an otherwise functional gene, wherein the pathology is selected from the group consisting of Duchenne Muscular Dystrophy, cystic fibrosis, Hurler's syndrome, and Becker muscular dystrophies, and wherein the stop codon is selected from the group consisting of: UAAC, UAGC, UGAC, UAAG, UAGG, UGAG, UAAU, UAGU, UGAU, UAAA, UAGA, and UGAA; and
formulating a mixture of a therapeutically effective dose of an aminoglycoside enriched in an isolated and purified compound having the following formula, or a pharmaceutically acceptable salt thereof:
wherein, R 1 and R 3 are H, and R 2 is CH 3 , and wherein the compound is present in said formulation at a level sufficient to reduce the cellular toxicity of the amino glycoside; and administering a therapeutically effective dose of said formulation to the patient.
4. The method according to claim 3 , wherein the stop codon is UAGC.